Important Notice for Pharmaceutical Drug Manufacturers

This notice is to inform you that the Texas Department of Health Services (DSHS) is now implementing the remainder of Texas Health and Safety Code Chapter 441. This may impact your company.

House Bill 2536, 86th Legislative Regular Session (2019), added new Chapter 441 to the Texas Health and Safety Code. Chapter 441, entitled Drug Cost Transparency, requires pharmaceutical drug manufacturers to annually report to DSHS current wholesale acquisition cost information for U.S. Food and Drug Administration (FDA)-approved drugs sold in or into Texas. Manufacturers were required to submit these reports for 2020 by March 15, 2020.

Chapter 441 also requires manufacturers to separately report specific information about certain wholesale acquisition cost increases. DSHS is now accepting specific information related to wholesale acquisition cost information price increases.